trelagliptin
Ligand Summary
Trelagliptin is an orally active dipeptidyl peptidase (DPP)-4 inhibitor developed by Takeda and approved in Japan for the treatment of type 2 diabetes mellitus.
PubChem: 15983988
ChEMBL: CHEMBL1650443
DrugCentral: 5013
LyCHI: AK17MSZBKLPC
Target Activities
5 Activities
Items per page:
10
1 – 5 of 5
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
Ki | ||||||
IC50 | INHIBITOR | |||||